Research Progress on Application of CRISPR/Cas Genome Editing Technology in Hematological Diseases -Review.
10.7534/j.issn.1009-2137.2016.04.061
- Author:
Liu-Yan XIN
1
;
Ai-Fei LIU
2
;
Si-Si ZHONG
3
;
Yi-Jian CHEN
4
,
5
Author Information
1. Gannan Medical College, Department of Hematology, The First Affiliated Hospital of Gannan Medical College,Ganzhou 341000,Jiangxi Province,China.
2. Gannan Medical College, The First Affiliated Hospital of Gannan Medical College,Ganzhou 341000,Jiangxi Province,China.
3. Department of Hematology, The First Affiliated Hospital of Gannan Medical College,Ganzhou 341000,Jiangxi Province,China.
4. Gannan Medical College, The First Affiliated Hospital of Gannan Medical College,Ganzhou 341000,Jiangxi Province,China.E-mail:chenyj2005@
5. com.
- Publication Type:Journal Article
- MeSH:
CRISPR-Cas Systems;
Gene Editing;
Genetic Techniques;
Genome;
Hematologic Diseases;
Humans;
Phenotype
- From:
Journal of Experimental Hematology
2016;24(4):1284-1288
- CountryChina
- Language:Chinese
-
Abstract:
CRISPR/Cas genome editing technology is a newly developed powerful tool for genetic manipulation, which can be used to manipulate the genome at specific locations precisely, to restore the function of genetic defect cells, and to develop various disease models. In recentl years, with the advances of precise genome manipulation, CRISPR/Cas technology has been applied to many aspects of diseases research and becomes an unique tool to investigate gene function and discover new therapeutic targets for genetic diseases. Nowadays, CRISPR/Cas technology has been a hot research point in agriculture, graziery, biotechnology and medicine. This review focuses on the recent advances in CRISPR/Cas technology and its application in hematological diseases.
